Physicians' Academy for Cardiovascular Education

Recent advances in lowering CV risk with antidiabetic agents

3' education - Feb. 12, 2016 - Boston, MA, USA - Prof Stephen Wiviott

Video navigation menu

  • What can be done about the increasing prevalance of diabetes and associated CV disease? 0:15
  • Assessing CV benefit of diabetes agents in large CV outcomes trials 2:41
  • Targeting the SGLT2 transporter to lower blood glucose exerts various effects 3:24
  • Are the EMPA-REG OUTCOMES results reproducible? 7:27
  • Where are we now with anti-diabetic treatment in relation to lowering CV risk? 8:36

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: